Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May

About this update from Opus Genetics, Inc.

[{"type":"image","alt":"Opus Genetics, Inc.","displaySize":"","headline":null,"caption":"Opus Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":129,"url":"https://media.zenfs.com/en/globenewswire.com/5903b8b33116d080342bdaf2c6a1b0bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xl5Pbyep4pXJ5VZR6DH1.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5903b8b33116d080342bdaf2c6a1b0bd","width":300,"height":129}},"lazy":false},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other treatments for ophthalmic disorders, today announced presentations related to its IRD gene therapy programs at these upcoming scientific conferences in May.","length":384,"tagName":"p"},{"type":"text","content":"Presentation Details","length":20,"tagName":"p"},{"type":"text","content":"American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting","length":71,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:10%;width:10%;min-width:10%;vertical-align:top;","val":[{"type":"text","content":"Title:","length":6,"tagName":"p","attribs":{}}]},{"style":"max-width:90%;width:90%;min-width:90%;vertical-align:top;","val":[{"type":"text","content":"Evaluation of MERTK gene therapy in RCS rats following a single bilateral subretinal injection","length":94,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Date/ time:","length":11,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"May 13, 2025, from 6:00 to 7:00 pm ET","length":37,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Presenter:","length":10,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"Mayur Choudhary Ph.D., Principal Scientist, Opus Genetics","length":57,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Format:","length":7,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"Poster","length":6,"tagName":...

More updates from Opus Genetics, Inc.